Where’s the imaging at HIMSS 2011? The significance of digital radiology and cardiology, and the complex issues relating their “meaningful use” and integration into the EHR once again are not being discussed in Orlando, Aunt Minnie reports.
More dispatches from HIMSS: The organization’s top priority? Keeping Health IT bipartisan; Meaningful use remains the top goal for HIT execs; The regulatory process isn’t pretty, says an HHS official; Keep your hands off our federal subsidies, says HIMSS government relations chief.
Where’s the ‘smartest biotech investor’ putting his money? Ronald Kirk (and his $2.2 billion net worth) may be the “best biotech investor ever.” His next big thing? Intrexon, a secretive research-stage company that is working on the hot new field of synthetic biology.
The big IPO: Mega-hospital operator HCA has refiled documents related to its planned initial public offering. The key numbers: $27 to $30 per share for a fundraise that could reach as high as $4.3 billion.
Hard times: Medtronic plans to lay off up to 2,000 employees; Takeda recalls a 40-year-old anti-inflammatory drug; Delcath has its New Drug Application sent back by the FDA, which requested additional information.
Single-payer healthcare in Vermont? Probably not, but thanks for trying. The state’s governor formally introduced a proposal to create a single-payer health system by 2014, but the measure would require an act of Congress to take effect as proposed.
Is your company’s CEO overconfident? If so, stick with that company.
Dealflow: Gilead Sciences will pay up to $600 million for Calistoga Pharmaceuticals; Acetylon Pharma raises $12.4 million; Forest Laboratories to buy Clinical Data (a Ronald Kirk company) for $1.2 billion.